{"id":"hum0022","version":1,"url":"https://humandbs.dbcls.jp/research/hum0022/v1","datePublished":"2015-02-02","versions":[{"version":1,"datePublished":"2015-02-02"}],"title":{"ja":"同種造血幹細胞移植後ドナー由来白血病発症にかかわる分子機構の解析","en":"Analysis of the Molecular Mechanism for Developing Donor-Origin Leukemia after Allogeneic Stem Cell Transplantation."},"summary":{"aims":{"ja":"白血病患者への治療として実施される造血幹細胞移植後に発症する、移植ドナー細胞由来白血病（Donor Cell Leukemia：DCL）の発症メカニズムの解明","en":"To clarify the molecular mechanism underlying malignant transformation of Donor-cell derived leukemia (DCL)."},"methods":{"ja":"Illumina HiSeq 2000を使用したExome解析","en":"Whole Exome Sequencing was performed by using of Illumina HiSeq 2000."},"targets":{"ja":"DCL患者1症例と移植ドナー1名","en":"One DCL patient and one donor"},"url":{"ja":null,"en":null}},"listingSummary":{"methods":{"ja":"配列決定","en":"Sequencing"},"targets":{"ja":"白血病：1症例\nドナー：1名\n（日本人）","en":"1 DCL (5 Samples from Each Stage)\n1 Donor\n(Japanese)"},"typeOfData":{"ja":"NGS\n（Exome）","en":"NGS\n(Exome)"}},"releaseNote":{"ja":"このバージョンでは、移植ドナー細胞由来白血病患者1症例の各病期（白血病、その寛解期、再発期、ドナー由来白血病後期）における骨髄中白血病細胞・末梢血から抽出したDNA、および、移植ドナー1例の末梢血から抽出したDNAを用いたExome解析の結果をFastqファイルにて提供する。SureSelect Kitを用いてExon領域にしぼり、Illumina 社 HiSeq 2000にて平均長100塩基のDNA断片を解読した（Paired-end）。","en":"From a single patient, following specimens were obtained for initial acute myeloid leukemia, remission stage, relapsed stage, and DCL at late stage. Donor cells were also obtained. Genomic DNA was extracted from blood cells, and subjected to the enrichment of exon fragments by using SureSelect system (Agilent). We sequenced 100~105 bases from both ends of them with a Illumina HiSeq2000 system with paired-end mode."},"dataProviders":[{"name":{"ja":"清井 仁","en":"Hitoshi Kiyoi"},"organization":{"name":{"ja":"名古屋大学大学院 医学系研究科 血液・腫瘍内科学","en":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine"}}}],"researchProjects":[{"name":{"ja":"次世代がん研究戦略推進プロジェクト「創薬コンセプトに基づく戦略的治療デザインの確立」白血病ゲノムに基づく層別化治療の確立","en":"Project for Development of Innovative Research on Cancer Therapeutics , Team for Strategic Therapy Design"},"url":{"ja":null,"en":null}}],"grants":[{"title":{"ja":"臨床1：創薬コンセプトに基づく戦略的治療デザインの確立 / 臨床1-①：白血病ゲノムに基づく層別化治療の確立","en":"Therapy 1 : Establishment of the strategic therapy design based on the development of molecular-targeted drugs / Therapy 1 - ① : Establishment of the optimal remedy based on the leukemia genome study"},"agency":{"ja":"次世代がん研究シーズ戦略的育成プログラム（P-DIRECT）","en":"Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT)"},"grantIds":null}],"relatedPublications":[{"title":"Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation","doi":"https://doi.org/10.1038/leu.2013.278","datasets":["JGAD000017"]}],"datasets":["JGAD000017"],"controlledAccessUsers":[{"principalInvestigator":{"ja":"小川 誠司","en":"Seishi Ogawa"},"affiliation":{"ja":"腫瘍生物学講座, 京都大学","en":"Department of Pathology and Tumor biology, Kyoto University"},"country":{"ja":"日本","en":"Japan"},"researchTitle":{"ja":"造血器腫瘍における遺伝子異常の網羅的解析","en":"The comprehensive analysis of gene mutations in the patients with myeloid neoplasms."},"periodStart":"2015-12-21","periodEnd":"2016-03-22","datasets":["JGAD000017"]}]}